Sanofi SA, of Paris, said the FDA has accepted for review the supplemental biologics license application of Dupixent (dupilumab) as an add-on maintenance treatment in certain adults and adolescents (12 and older) with moderate to severe asthma. The PDUFA target action date is Oct. 20.